Cancer can be tough but there is something that can still break it.

Uterine cancer is one of the commonest gynecological cancers, especially in white Americans. It is the seventh most common disorder across the world.  It occurs most often in postmenopausal women (up to 80% of cases), about 5% diagnosed less than 40 years of age. According to the American Cancer Society (ACS), more than 52,500 newly cases are diagnosed, while more than 8,500 cases of deaths with uterine cancer that estimated in 2014. To increases survival rate of this cancer, researchers applied immunotherapy for the treatment of this cancer.

There is no effective screening programmed, but occasionally cervical smears containing endometrial cancer cells or double thickness endometrial ultrasonic thickness of 4mm or more indicates a need for endometrial sampling．

www.gapsos.com

The actual cause of this cancer is unknown. There can be no doubt that estrogen can alter the behavior of this tumour but there is still a question about estrogen as a primary causal agent. Estrogen secreting tumors of the ovary are associated with an increased incidence of endometrial carcinoma. Estrogen given alone as in postmenopausal Hormone Replacement Therapy (HRT).

Approximately 75% of cases of this cancer occur in the postmenopausal period when estrogen values are low and progesterone is absent. Null parity and polycystic ovary syndrome (PCOS) with defective progesterone synthesis carry an increased risk. After long term use of oral contraceptives (birth control pills) reduces the incidence of both endometrial and ovarian carcinomas.The usual presenting symptom of this cancer is postmenopausal bleeding which carries a 10% risk of associated malignancy in the absence of hormone replacement therapy. 

The treatment of uterine cancer with immunotherapy that involves Dentritic Cell immunotherapy, adoptive T cell therapy, and immune-modulator.  In dentritic cell immunotherapy, processed antigens have capability to enhance the potential of patient’s immune system to fight with specific cancer cells. Immature form of dentritic cells are loaded tumour antigens such as tumour lysate, which exist as mRNA. (Immatureforms of dentritic cells are able to capturedand processed antigens, after interaction with chemokine receptors and its ligands, this cell migrate to the lymph nodes). 

Global Allied Pharmaceuticals (GAP) has new technology to developed advanced treatment of uterine cancer on the basis of immune oncology and immunotherapy. GAP has a team of experts for conducting clinical trials for new immunotherapeutic cancer agents, which are used in immunotherapy.

For more information kindly visit us at www.gapsos.com